Literature DB >> 19240835

Giant Cholesteatoma: Recommendations for Follow-up.

Leontien I Geven1, Jef J S Mulder, Kees Graamans.   

Abstract

This report presents the management of five patients who presented with giant recurrent or residual cholesteatoma after periods of 2 to 50 years. Their case histories are highly diverse, but all provide evidence of the need for long-term follow-up.

Entities:  

Keywords:  Cholesteatoma; middle ear; skull base; surgery

Year:  2008        PMID: 19240835      PMCID: PMC2637064          DOI: 10.1055/s-0028-1086054

Source DB:  PubMed          Journal:  Skull Base        ISSN: 1531-5010


  19 in total

1.  Can MRI replace a second look operation in cholesteatoma surgery?

Authors:  D Vanden Abeele; E Coen; P M Parizel; P Van de Heyning
Journal:  Acta Otolaryngol       Date:  1999       Impact factor: 1.494

2.  Ten-year results of canal wall down mastoidectomy for acquired cholesteatoma.

Authors:  E Vartiainen
Journal:  Auris Nasus Larynx       Date:  2000-07       Impact factor: 1.863

3.  Management of acquired cholesteatoma of the middle ear and the mastoid by combined approach tympanoplasty: a long-term view.

Authors:  T R Kapur; S Jayarmachandran
Journal:  Clin Otolaryngol Allied Sci       Date:  1997-02

4.  Treatment of sinus cholesteatoma. Long-term results and recurrence rate.

Authors:  T Lau; M Tos
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1988-12

5.  Revision chronic ear surgery.

Authors:  David M Kaylie; Edward K Gardner; C Gary Jackson
Journal:  Otolaryngol Head Neck Surg       Date:  2006-03       Impact factor: 3.497

6.  Intact canal wall tympanoplasty with mastoidectomy for cholesteatoma: long-term follow-up.

Authors:  S E Kinney
Journal:  Laryngoscope       Date:  1988-11       Impact factor: 3.325

7.  The value of diffusion-weighted MR imaging in the diagnosis of primary acquired and residual cholesteatoma: a surgical verified study of 100 patients.

Authors:  Jean-Philippe Vercruysse; Bert De Foer; Marc Pouillon; Thomas Somers; Jan Casselman; Erwin Offeciers
Journal:  Eur Radiol       Date:  2006-03-03       Impact factor: 5.315

8.  The value of magnetic resonance imaging in the diagnosis of residual or recurrent acquired cholesteatoma after canal wall-up tympanoplasty.

Authors:  Gert Jeunen; Christian Desloovere; Robert Hermans; Vincent Vandecaveye
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

9.  Attic cholesteatoma. Recurrence rate related to observation time.

Authors:  M Tos; T Lau
Journal:  Am J Otol       Date:  1988-11

Review 10.  Cholesteatoma surgery: the individualized technique.

Authors:  S Karmarkar; S Bhatia; E Saleh; G DeDonato; A Taibah; A Russo; M Sanna
Journal:  Ann Otol Rhinol Laryngol       Date:  1995-08       Impact factor: 1.547

View more
  5 in total

1.  Extensive intratemporal cholesteatomas: presentation, complications and surgical outcomes.

Authors:  Ashish Vashishth; Tilak Raj Singh Nagar; Shantanu Mandal; Vellore Pattabhiram Venkatachalam
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-08       Impact factor: 2.503

2.  A Case Report of a Giant Cholesteatoma.

Authors:  Neelam Sood; Binit Kumar Khandelia; Gitanjali Bugnait
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Optimal Duration of MRI Follow-up to Safely Identify Middle Ear Residual Cholesteatoma.

Authors:  A-L Fourez; M Akkari; G Gascou; P-H Lefevre; C Duflos; A Kaderbay; M Mondain; F Venail
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-15       Impact factor: 4.966

4.  Giant Petrous Bone Cholesteatoma: Combined Microscopic Surgery and an Adjuvant Endoscopic Approach.

Authors:  Giannicola Iannella; Ersilia Savastano; Benedetta Pasquariello; Massimo Re; Giuseppe Magliulo
Journal:  J Neurol Surg Rep       Date:  2016-03

5.  Uniform Registration Agreements on Cholesteatoma Care: A Nationwide Consensus Procedure.

Authors:  Fleur A Ten Tije; Robert J Pauw; Jozé C Braspenning; Raphael J B Hemler; Annette J Ter Schiphorst; Erik F Hensen; Lisa van der Putten; Sophia E Kramer; Paul Merkus
Journal:  Otol Neurotol       Date:  2020-09       Impact factor: 2.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.